Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29980
Title: | Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions | Authors: | MARTENS, Pieter Lambeets, Seppe Lau, Chirik Wah DUPONT, Matthias MULLENS, Wilfried |
Issue Date: | 2019 | Publisher: | TAYLOR & FRANCIS LTD | Source: | ACTA CARDIOLOGICA, 74(2), p. 115-122 | Abstract: | Background: Sacubitril/valsartan reduced heart failure (HF)-admissions and cardiovascular mortality in the PARADIGM-HF-trial. However, real-world patients are often frailer and less able to tolerate high doses of sacubitril/valsartan. Methods: We performed a retrospective analysis of consecutive patients prescribed sacubitril/valsartan in a single tertiary HF-clinic between December 2016 and January 2018. HF-admissions were assessed in a paired fashion, comparing the amount of antecedent HF-episodes with incident HF-episodes after the initiation. Baseline risk for adverse events was assessed by the EMPHASIS-HF-risk-score. Results: A total of 201-HF-patients were retrospectively identified (age = 68 +/- 11 years, ejection fraction = 29 +/- 8%). Real world patients were older, had higher serum creatinine and a higher New-York Heart-Association (NYHA)-class (p<.05 for all) than in the PARADIGM-HF trial. Over a mean duration of 221 +/- 114 days after initiation of sacubitril/valsartan a total of 23-individual patients experienced at least one HF-episodes. Over the same time period preceding initiation of sacubitril/valsartan, 51 individual patients experienced a HF-episodes (p<.001). Sacubitril/valsartan significantly reduced the rate of incident vs. antecedent HF-admissions, in patients with low or high baseline NYHA-class (II vs. III and IV; p value = 0.019 respectively p =.004) or patients with an EMPHASIS-HF risk score below or above the mean (p =.002 respectively p =.016). Patients older than 75-years exhibited a trend towards HF-reduction. Higher doses of sacubitril/ valsartan were associated with more reduction in incident versus antecedent HF-episodes. Conclusion: Despite being frailer and older, real-world patients exhibit a significant and early reduction in incident HF-hospitalisations following initiation of sacubitril/valsartan. Higher doses might be associated with more reduction in HF-admissions, underscoring the importance of dose uptitration. | Notes: | [Martens, Pieter; Lambeets, Seppe; Lau, Chirik Wah; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, Schiepse Bos 6, B-3600 Genk, Belgium. [Martens, Pieter] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium. | Keywords: | Sacubitril/valsartan; pharmacology; heart failure; hospitalizations;Sacubitril/valsartan; pharmacology; heart failure; hospitalizations | Document URI: | http://hdl.handle.net/1942/29980 | ISSN: | 0001-5385 | e-ISSN: | 1784-973X | DOI: | 10.1080/00015385.2018.1473825 | ISI #: | 000490261700004 | Rights: | 2018 Belgian Society of Cardiology | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
martens2018 (1).pdf Restricted Access | Published version | 1.16 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
9
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
19
checked on Oct 14, 2024
Page view(s)
114
checked on Jul 22, 2022
Download(s)
104
checked on Jul 22, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.